Immatics N.V. (IMTX)
NASDAQ: IMTX · Real-Time Price · USD
6.05
-0.38 (-5.84%)
Aug 13, 2025, 3:05 PM - Market open

Company Description

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States.

The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.

Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage.

The company develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial.

The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications.

Immatics N.V. is headquartered in Tübingen, Germany.

Immatics N.V.
Immatics logo
CountryGermany
IndustryBiotechnology
SectorHealthcare
Employees682
CEOHarpreet Singh

Contact Details

Address:
Paul-Ehrlich-Strasse 15
Tübingen, 72076
Germany
Phone49 7071 5397 0
Websiteimmatics.com

Stock Details

Ticker SymbolIMTX
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyEUR
CIK Code0001809196
CUSIP NumberN44445109
ISIN NumberNL0015285941
SIC Code2836

Key Executives

NamePosition
Dr. Harpreet Singh Ph.D.Chief Executive Officer, MD, Member of Management Board and Executive Director
Dr. Toni Weinschenk Ph.D.Co-Founder and Chief Innovation Officer
Arnd Christ MBAChief Financial Officer
Steffen Walter Ph.D.Chief Operations Officer
Edward A. SturchioGeneral Counsel and Secretary
Dr. Carsten Reinhardt M.D., Ph.D.Chief Development Officer
Dr. Rainer Kramer Ph.D.Chief Business Officer and Site Head Munich
Cedrik M. Britten M.D.Chief Medical Officer
Jordan SilversteinHead of Strategy
Dr. Hans-Georg Rammensee Ph.D.Co-Founder and Member of the Scientific Advisory Board

Latest SEC Filings

DateTypeTitle
Aug 13, 20256-KReport of foreign issuer
Aug 12, 2025SCHEDULE 13G/AFiling
Jul 2, 2025S-8Securities to be offered to employees in employee benefit plans
Jul 1, 202525-NSEFiling
Jun 18, 20256-KReport of foreign issuer
Jun 2, 20256-KReport of foreign issuer
Jun 2, 20256-KReport of foreign issuer
May 13, 20256-KReport of foreign issuer
May 12, 2025SCHEDULE 13G/AFiling
May 2, 2025SCHEDULE 13G/AFiling